Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: A hypothesis

Medical Hypotheses

Volumn 76, Issue 4, 2011, Pages 576-584

  Blum, Kenneth ^a   Gold, Mark S ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; BROMOCRIPTINE; CATECHOLAMINE METHYLTRANSFERASE INHIBITORY AGENT; DOPAMINE; DOPAMINE 2 RECEPTOR; ENDORPHIN; ENKEPHALIN; ENZYME PRECURSOR; MESSENGER RNA; NEUROTRANSMITTER; NUTRACEUTICAL; SEROTONIN; UNCLASSIFIED DRUG;

ADOLESCENT; AFTERCARE; ALCOHOLISM; ALLELE; ARTICLE; CLINICAL TRIAL (TOPIC); DETOXIFICATION; DISEASE PREDISPOSITION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; EUPHORIA; GENETIC SCREENING; HEREDITY; HIGH RISK POPULATION; HUMAN; HYPOTHESIS; LIMBIC CORTEX; MULTIPLE DRUG ABUSE; NEUROCHEMISTRY; NONHUMAN; OBESITY; PERSONALITY DISORDER; PSYCHOTHERAPY; RELAPSE; RESIDENTIAL CARE; SUBSTANCE ABUSE; SUPERSENSITIVITY; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADOLESCENT; BEHAVIOR, ADDICTIVE; BRAIN; DOPAMINE; DOPAMINE AGONISTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; PSYCHOTHERAPY; RECURRENCE; REWARD; SUBSTANCE-RELATED DISORDERS;

EID: 79952312209     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.01.005     Document Type: Article

References (135)

1. Coffey R.M., Buck J.A., Kassed C.A., et al. Transforming mental health and substance abuse data systems in the United States. Psychiatr Serv 2008, 59(11):1257-1263.
2. Thanos P.K., Rivera S.N., Weaver K., et al. Dopamine D2R DNA transfer in dopamine D2 receptor-deficient mice. effects on ethanol drinking. Life Sci 2005, 77(2):130-139.
3. Dackis C.A., Gold M.S. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Bio Rev 1985, 9(3):469-477.
4. Blum K., Calhoun W., Merritt J., Wallace J.E. L-DOPA: effect on ethanol narcosis and brain biogenic amines in mice. Nature 1973, 242(5397):407-409.
5. Blum K., Braverman E.R., Holder J.M., et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 2000, 32:1-112.
6. Koob G.F. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 2009, 56:18-31.
7. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol Rev 1987, 94(4):469-492.
8. Koob G.F., Le Moal M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci 2008, 363(1507):3113-3123.
9. Berridge K.C., Kringelbach M.L. Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology (Berl) 2008, 199(3):457-480.
10. Esch T., Stefano G.B. The neurobiology of stress management. Neuro Endocrinol Lett 2010, 31(1):30.
11. White M.J., Lawford B.R., Morris C.P., Young R.M. Interaction between DRD2 C957T polymorphism and an acute psychosocial stressor on reward-related behavioral impulsivity. Behav Genet 2009, 39:285-295.
12. London E.D., Berman S.M., Mohammadian P., et al. Effect of the TaqIA polymorphism on ethanol response in the brain. Psychiatry Res 2009, 174(3):163-170.
13. Blum K., et al. Genetic addiction risk score(GARS) analysis: exploratory development of polymorphic risk alleles in poly-drug addicted males. IIOAD 2010, 1(2):1-14.
14. Seeger T.F., Gardner E.L. Enhancement of self-stimulation behavior in rats and monkeys after chronic neuroleptic treatment: evidence for mesolimbic supersensitivity. Brain Res 1979, 175(1):49-57.
15. Blum K., Chen T.J., Downs B.W., et al. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART). Postgrad Med 2009, 121(6):176-196.
16. Kirsch P., Reuter M., Mier D., et al. Imaging gene-substance interactions: the effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward. Neurosci Lett 2006, 405(3):196-201.
17. Blum K., Noble E.P., Sheridan P.J., Montgomery A., Ritchie T., Jagadeeswaran P., et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 1990, 263(15):2055-2060.
18. Noble E.P., Blum K., Ritchie T., et al. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991, 48:648-654.
19. Jönsson E.G., Nöthen M.M., Grünhage F., et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999, 4(3):290-296.
20. Xu K., Lichtermann D., Lipsky R.H., et al. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch Gen Psychiatry 2004, 61(6):597-606.
21. Volkow N.D., Wang G.J., Fowler J.S., et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 1999, 156(9):1440-1443.
22. Pinto E., Reggers J., Gorwood P., et al. The TaqI A DRD2 polymorphism in type II alcohol dependence. a marker of age at onset or of a familial disease?4. Alcohol 2009, 43(4):271-275.
23. Persico A.M., Bird G., Gabbay F.H., Uhl G.R. D2 dopamine receptor gene TaqI A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers. Biol Psychiatry 1996, 40(8):776-784.
24. Li Y., Shao C., Zhang D., et al. The effect of dopamine D2, D5 receptor and transporter (SLC6A3) polymorphisms on the cue-elicited heroin craving in Chinese. Am J Med Genet B Neuropsychiatr Genet 2006, 141B(3):269-273.
25. Medland S.E., Neale M.C. An integrated phenomic approach to multivariate allelic association. Eur J Hum Genet 2010, 18(2):233-239.
26. Bergen A.W., Conti D.V., Van Den Berg D., et al. Dopamine genes and nicotine dependence in treatment-seeking and community smokers. Neuropsychopharmacology 2009, 34:2252-2264.
27. Davis C.A., Levitan R.D., Reid C., et al. Dopamine for "wanting" and opioids for "liking": a comparison of obese adults with and without binge eating. Obesity 2009, 17(6):1220-1225.
28. Ibáñez A., Blanco C., Donahue E., et al. Psychiatric comorbidity in pathological gamblers seeking treatment. Am J Psychiatry 2001, 158(10):1733-1735.
29. Emanuele E., Brondino N., Pesenti S., Re S., Geroldi D. Genetic loading on human loving styles. Neuro Endocrinol Lett 2007, 28(6):815-821.
30. Kopecková M., Paclt I., Petrásek J., Pacltová D., Malíková M., Zagatová V. Some ADHD polymorphisms (in genes DAT1, DRD2, DRD3, DBH, 5-HTT) in case-control study of 100 subjects 6-10 age. Neuro Endocrinol Lett 2008, 29(2):246-251.
31. Lee C.C., Chou I.C., Tsai C.H., Wang T.R., Li T.C., Tsai F.J. Dopamine receptor D2 gene polymorphisms are associated in Taiwanese children with Tourette syndrome. Pediatr Neurol 2005, 33(4):272-276.
32. Comings D.E., Comings B.G., Muhleman D., et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991, 266(13):1793-1800.
33. Blum K., Braverman E.R., Wu S., et al. Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB). Mol Psychiatry 1997, 2(3):239-246.
34. Hoenicka J., Ponce G., Jiménez-Arriero M.A., et al. Association in alcoholic patients between psychopathic traits and the additive effect of allelic forms of the CNR1 and FAAH endocannabinoid genes, and the 3′ region of the DRD2 gene. Neurotox Res 2007, 11(1):51-60.
35. Blum K., Sheridan P.J., Wood R.C., et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 1996, 89(7):396-400.
36. Lee J., Ramchandani V.A., Hamazaki K., et al. A critical evaluation of influence of ethanol and diet on salsolinol enantiomers in humans and rats. Alcohol Clin Exp Res 2010, 34(2):242-250.
37. Franklin K.M., Engleman E.A., Ingraham C.M., et al. A single, moderate ethanol exposure alters extracellular dopamine levels and dopamine d receptor function in the nucleus accumbens of wistar rats. Alcohol Clin Exp Res 2009, 33(10):1721-1730.
38. McBride W.J., Schultz J.A., Kimpel M.W., et al. Differential effects of ethanol in the nucleus accumbens shell of alcohol-preferring (P), alcohol-non-preferring (NP) and Wistar rats: a proteomics study. Pharmacol Biochem Behav 2009, 92(2):304-313.
39. Rodd Z.A., Gryszowka V.E., Toalston J.E., et al. The reinforcing actions of a serotonin-3 receptor agonist within the ventral tegmental area: evidence for subregional and genetic differences and involvement of dopamine neurons. J Pharmacol Exp Ther 2007, 321(3):1003-1012.
40. Nowak K.L., McBride W.J., Lumeng L., Li T.K., Murphy J.M. Blocking GABA(A) receptors in the anterior ventral tegmental area attenuates ethanol intake of the alcohol-preferring P rat. Psychopharmacology (Berl) 1998, 139(1-2):108-116.
41. McBride W.J., Chernet E., Russell R.N., et al. Regional CNS densities of monoamine receptors in alcohol-naive alcohol-preferring P and nonpreferring NP rats. Alcohol 1997, 14(2):141-148.
42. Weiss F., Mitchiner M., Bloom F.E., Koob G.F. Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacology (Berl) 1990, 101(2):178-186.
43. Blum K., Trachtenberg M.C., Elliott C.E., et al. Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: double-blind placebo-controlled study of the nutritional adjunct SAAVE. Alcohol 1988, 5(6):481-493.
44. Blum K., Trachtenberg M.C., Ramsay J.C. Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: a pilot study. Int J Addict 1988, 23(9):991-998.
45. DeFrance J.F., Hymel C., Trachtenberg M.C., et al. Enhancement of attention processing by Kantroll in healthy humans: a pilot study. Clin Electroencephalogr 1997, 28(2):68-75.
46. Brown R.J., Blum K., Trachtenberg M.C. Neurodynamics of relapse prevention: a neuronutrient approach to outpatient DUI offenders. J Psychoactive Drugs 1990, 22(2):173-187.
47. Trachtenberg M.C., Blum K. Improvement of cocaine-induced neuromodulator deficits by the neuronutrient Tropamine. J Psychoactive Drugs 1988, 20(3):315-331.
48. Blum K., Chen A.L., Chen T.J., et al. LG839: anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome. Adv Ther 2008, 25(9):894-913.
49. Blum K., Chen T.J.H., Downs B.W., et al. Synaptamine (SG8839) an amino-acid enkephalinase inhibition nutraceutical improves recovery of alcoholics, a subtype of Reward Deficiency Syndrome (RDS). Trends Appl Sci Res 2007, 2(2):132-138.
50. Blum K., Trachtenberg M.L., Cook D.W. Neuronutrient effects on weight loss in carbohydrate bingers: an open clinical trial. Curr Ther Res 1990, 48(2):217-233.
51. Blum K., Allison D., Trachtenberg M.C., Williams R.W., Loeblich L.A. Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30day inpatient treatment program by the neuronutrient Tropamine. Curr Ther Res 1988, 43:1204-1214.
52. Blum K., Chen A.L.C., Chen T.J.H., et al. Putative targeting of dopamine D2 receptor function in Reward deficiency Syndrome (RDS) by Synaptamine Complex Variant (KB220): clinical trial showing anti-anxiety effects. Gene Ther Mol Biol 2009, 13.
53. Blum K., Chen T.J.H., Williams L., et al. A short term pilot open label study of LG839, a customized DNA directed nutraceutical in obesity: exploring nutrigenomics. Gene therapy and Mol Biol 2008, 12:371-382.
54. Miller D., Manka M., Miller M., et al. Acute intravenous synaptamine complex [KB220]™ variant "Normalizes" abnormal neurological activity in protracted abstinence of alcohol and opiate patients using Quantitative Electroencephalographic (QEEG) and neurotransmitter genetic analysis: pilot two case reports. Postgrad Med 2010, 122(6):188-213.
55. Blum K., Chen T.J.H., Morse S., et al. Overcoming qEEG Abnormalities and reward gene deficits during protracted abstinence in psychostimulant abusers utilizing putative dopamine D2 agonist therapy. Postgrad Med 2010, 122(6):214-226.
56. Rouillard C., Bédard P.J., Falardeau P., Dipaolo T. Behavioral and biochemical evidence for a different effect of repeated administration of L-dopa and bromocriptine on denervated versus non-denervated striatal dopamine receptors. Neuropharmacology 1987, 26(11):1601-1606.
57. Rihmer Z., Purebl G., Faludi G., Halmy L. Association of obesity and depression. Neuropsychopharmacol Hung 2008, 4:183-189.
58. Malhotra T., Rosenzweig I. Baclofen withdrawal causes psychosis in otherwise unclouded consciousness. J Neuropsychiatry Clin Neurosci 2009, 21(4):476.
59. Suda A., Kawanishi C., Kishida I., et al. Dopamine D2 receptor gene polymorphisms are associated with suicide attempt in the Japanese population. Neuropsychobiology 2009, 59(2):130-134.
60. Rothman R.B., Blough B.E., Baumann M.H. Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp Clin Psychopharmacol 2008, 16(6):458-474.
61. Blum K., Chen A.L., Chen T.J., Braverman E.R., et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model 2008, 5:24.
62. Cocores J.A., Gold M.S. The Salted Food Addiction Hypothesis may explain overeating and the obesity epidemic. Med Hypotheses 2009, 73(6):892-899.
63. Miller N.S., Gold M.S. A hypothesis for a common neurochemical basis for alcohol and drug disorders. Psychiatr Clin North Am 1993, 16(1):105-117.
64. Gold M.S., Herkov M.J. Tobacco smoking and nicotine dependence. biological basis for pharmacotherapy from nicotine to treatments that prevent relapse. J Addict Dis 1998, 17(1):7-21.
65. Extein I.L., Gold M.S. Hypothesized neurochemical models for psychiatric syndromes in alcohol and drug dependence. J Addict Dis 1993, 12(3):29-43.
66. Merlo L.J., Carnes P.J., Gold M.S. Response to "Comorbid psychiatric diagnoses and their association with cocaine-induced psychosis in cocaine-dependent subjects" Am J Addict 2008, 17(3):247-248.
67. Gold M.S., Redmond D.E., Kleber H.D. Clonidine blocks acute opiate withdrawal symptoms. Lancet 1978, 2(8090):599-602.
68. Blum K., Briggs A.H., DeLallo L. Clonidine enhancement of ethanol withdrawal in mice. Subst Alcohol Actions Misuse 1983, 4(1):59-63.
69. Gold M.S., Byck R. Endorphins, lithium and naloxone: their relationship to pathological and drug induced manic euphoric states. Natl Inst Drug Abuse Res Monogr Ser 1978, 19:192-209.
70. Blum K., Wallace J.E., Hall W.C. A commentary on the pathogenesis and biochemical profile of alcohol-induced depression. J Psychoactive Drugs 1986, 18(2):161-162.
71. Gold M.S., Pottash A.C., Sweeney D., Martin D., Extein I. Antimanic, antidepressant, and antipanic effects of opiates: clinical, neuroanatomical, and biochemical evidence. Ann NY Acad Sci 1982, 398:140-150.
72. Gold M.S., Fox C.F. Antianxiety and opiates. Behav Brain Sci 1985, 5(3):486-487.
73. Blum K., Eubanks J.D., Wallace J.E., Hamilton H. Enhancement of alcohol withdrawal convulsions in mice by haloperidol. Clin Toxicol 1976, 9(3):427-434.
74. Dackis C., Gold M.S. Opiate addiction and depression: cause or effect?. Drug Alcohol Depend 1983, 11(1):105-109.
75. Gold M.S., Pearsall H.R. Hypothyroidism or is it depression?. Psychosomatics 1983, 24(7):646-657.
76. Braverman E.R., Blum K. Substance use disorder exacerbates brain electrophysiological abnormalities in a psychiatrically-ill population. Clin Electroencephalogr 1996, 27:5-27.
77. Gold M.S., Dackis C.A., Washton A.M. The sequential use of clonidine and naltrexone in the treatment of opiate addicts. Advances in Alcohol and Substance Abuse 1984, 3(3):19-39.
78. Blum K., Futterman S., Wallace J.E., Schwertner H.A. Naloxone-induced inhibition of ethanol dependence in mice. Nature 1977, 265(5589):49-51.
79. Blum K., Wallace J.E., Schwerter H.A., Eubanks J.D. Morphine suppression of ethanol withdrawal in mice. Experientia 1976, 32(1):79-82.
80. Blum K., Eubanks J.D., Wallace J.E., Schwertner H.A. Suppression of ethanol withdrawal by dopamine. Experientia 1976, 32(4):493-495.
81. Dackis C.A., Gold M.S., Pottash A.L. Central stimulant abuse: neurochemistry and pharmacotherapy. Adv Alcohol Subst Abuse 1986, 6(2):7-21.
82. Gold M.S., Verebey K. The psychopharmacology of cocaine. Psychiatric Annals 1984, 14(10):714-723.
83. Cocores J.A., Dackis C.A., Gold M.S. Sexual dysfunction secondary to cocaine abuse. J Clin Psychiatry 1986, 47(7):384-385.
84. Gold MS. Drugs of Abuse: a comprehensive series for clinicians. Vol. III Cocaine. New York and London: Plenum Medical Book Company; 1993.
85. Gold M.S. Is there a treatment or treatments for addiction?. Contemp Psychology 1993, 38:1119-1120.
86. Blum K., Chen T.J., Chen A.L., et al. Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS). Med Hypotheses 2010, 74(3):513-520.
87. Blum K., Chen A.L., Braverman E.R., et al. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat 2008, 4(5):893-918.
88. Blum K., Chen T.J., Meshkin B., et al. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis. Med Hypotheses 2007, 69(5):1054-1060.
89. Comings D.E., Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 2000, 126:325-341.
90. Gold M.S. Drugs of Abuse: A Comprehensive Series for Clinicians Vol. IV Tobacco 1995, Plenum Medical Book Company, New York.
91. Byars J.A., Frost-Pineda K., Jacobs W.S., Gold M.S. Naltrexone augments the effects of nicotine replacement therapy in female smokers. J Add Dis 2005, 24(2):49-61.
92. Gold M.S., Byars J.A., Frost-Pineda K., Pusey A.E. Substance use in women. Spec Issues Women's Health 2005, 105-150.
93. Chen A.L., Chen T.J., Braverman E.R., et al. Hypothesizing that marijuana smokers are at a significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers: evidenced based on statistical reevaluation of current literature. J Psychoactive Drugs 2008, 40(3):263-272.
94. Gold M.S., Frost Pineda K., Melker R.J. Physician suicide and drug abuse. Am J Psychiatry 2005, 16(7):1390.
95. Blum K., Briggs A.H., Trachtenberg M.C. Ethanol ingestive behavior as a function of central neurotransmission. Experientia 1989, 45(5):444-452.
96. Bruijnzeel A.W., Gold M.S. The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Res Rev 2005, 49(3):505-528.
97. Bruijnzeel A.W., Zislis G., Wilson C., Gold M.S. Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. Neuropsychopharmacology 2007, 32(4):955-996.
98. Finn D.A., Snelling C., Fretwell A.M., et al. Increased drinking during withdrawal from intermittent ethanol exposure is blocked by the CRF receptor antagonist d-Phe-CRF(12-41). Alcohol Clin Exp Res 2007, 31(6):939-949.
99. Blum K., Briggs A.H., Trachtenberg M.C., Delallo L., Wallace J.E. Enkephalinase inhibition: regulation of ethanol intake in genetically predisposed mice. Alcohol 1987, 4(6):449-456.
100. Blum K., Briggs A.H., Elston S.F., DeLallo L., Sheridan P.J., Sar M. Reduced leucine-enkephalin-like immunoreactive substance in hamster basal ganglia after long-term ethanol exposure. Science 1982, 216(4553):1425-1427.
101. Blum K., Elston S.F., DeLallo L., Briggs A.H., Wallace J.E. Ethanol acceptance as a function of genotype amounts of brain [Met]enkephalin. Proc Natl Acad Sci USA 1983, 80(21):6510-6512.
102. Blum K., Briggs A.H., Wallace J.E., Hall C.W., Trachtenberg M.A. Regional brain [Met]-enkephalin in alcohol-preferring and non-alcohol-preferring inbred strains of mice. Experientia 1987, 43(4):408-410.
103. Kleiner K., Jacobs W.S., Lenz-Brunsman B., Perri M.G., Frost-Pineda K., Gold M.S. Body mass index and alcohol use. J Add Dis 2004, 23(3):105-118.
104. Warren M., Frost-Pineda K., Gold M. Body mass index and marijuana use. J Add Dis 2004, 24(3):95-100.
105. James G.A., Gold M.S., Liu Y. Interaction of satiety and reward response to food stimulation. J Add Dis 2004, 23(3):23-37.
106. Hodgkins C.C., Cahill K.S., Seraphine A.E., Frost-Pineda K., Gold M.S. Adolescent drug addiction treatment and weight gain. J Add Dis 2004, 23(3):55-66.
107. Gold M.S. Obesity and eating disorders as an addiction. J Add Dis 2004, 23(3):1-3.
108. Jorandby L., Frost-Pineda K., Gold M.S. Addiction to Food and brain reward systems. Sexual Addiction and Compulsivity 2005, 12(2-3):201-217.
109. Almeyda T.D., Penn D.R., Hodgkins C., Frost-Pineda K., Gold M.S. Weight gain during substance abuse treatment: the dual problem of addiction and overeating in an adolescent population. J Addict Disease. 2007, 26:41-50.
110. Downs B.W., Chen A.L., Chen T.J., et al. Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map?. Med Hypotheses 2009, 73(3):427-434.
111. Oben J.E., Ngondi J.L., Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids Health Dis 2008, 13(7):44.
112. Blum K., Chen T.J., Meshkin B., et al. Reward deficiency syndrome in obesity: a preliminary cross-sectional trial with a Genotrim variant. Adv Ther 2006, 23(6):1040-1051.
113. Blum K., Chen T.J., Meshkin B., et al. Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Med Hypotheses 2007, 68(4):844-852.
114. Svetlov S., Kobiessy F.H., Gold M.S. Performance enhancing, non-prescription use of Ritalin: a comparison with amphetamines and cocaine. J Addict Disease 2007, 26(4):1-6.
115. Graham N.A., DuPont R.L., Gold M.S. Symptoms of ADHD or marijuana use?. Am J Psychiatry 2007, 164(6):973.
116. Graham N.A., Frost-Pineda K., Gold M.S. Tobacco and psychiatric dual disorders. J Addict Dis 2007, 26:5-12.
117. Cocores J.A., Davies R.K., Mueller P.S., Gold M.S. Cocaine abuse and adult attention deficit disorder. J Clin Psychiatry 1987, 48(9):376-377.
118. Gold M.S., Frost-Pineda K. Regarding "Is cigarette smoking a gateway to alcohol and illicit drug use disorders? A study of youths with and without attention deficit hyperactivity disorder" Biol Psychiatry 2006, 60(10):1166.
119. Braverman E.R., Chen T.J., Schoolfield J., et al. Delayed P300 latency correlates with abnormal Test of Variables of Attention (TOVA) in adults and predicts early cognitive decline in a clinical setting. Adv Ther 2006, 23(4):582-600.
120. Comings D.E., Chen T.J., Blum K., Mengucci J.F., Blum S.H., Meshkin B. Neurogenetic interactions and aberrant behavioral co-morbidity of attention deficit hyperactivity disorder (ADHD): dispelling myths. Theor Biol Med Model 2005, 23(2):50.
121. Blum K., Chen A.L., Braverman E.R., Comings D.E., Chen T.J., Arcuri V., et al. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat 2008, 4(5):893-918.
122. Bruijnzeel A.W., Lewis B., Bajpai L.K., Morey T.E., Dennis D.M., Gold M.S. Severe depressive-like behavior associated with fentanyl withdrawal in rats. Biol Psychiatry 2006, 59:477-480.
123. Liu J., Pan H., Gold M.S., Derendorf H., Bruijnzeel A.W. Effects of fentanyl dose and exposure duration on the affective and somatic signs of fentanyl withdrawal in rats. Neuropharmacology 2008, 55(5):812-818.
124. Bruijnzeel A.W., Marcinkiewcz C., Isaac S., Booth M.M., Dennis D.M., Gold M.S. The effects of buprenorphine on fentanyl withdrawal in rats. Psychopharmacology (Berl) 2007, 191(4):931-941.
125. Chen T.J., Blum K., Payte J.T., et al. Narcotic antagonists in drug dependence. pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. Med Hypotheses 2004, 63(3):538-548.
126. Blum K., Briggs A.H., DeLallo L. On the mechanism of methadone-induced alcohol consumption in humans. Subst Alcohol Actions Misuse 1982, 3(1-2):1-4.
127. Chen T.J., Blum K., Waite R.L., Meshkin B., Schoolfield J., Downs B.W., et al. Gene Narcotic Attenuation Program attenuates substance use disorder, a clinical subtype of reward deficiency syndrome. Adv Ther 2007, 24(2):402-414.
128. Kobeissy F.H., Jeung J.A., Warren M.W., Geier J.E., Gold M.S. Changes in leptin, ghrelin, growth hormone and neuropeptide-Y after an acute model of MDMA and methamphetamine exposure in rats. Addict Biol 2008, 13(1):15-25.
129. Merlo L.J., Gold M.S. Prescription opioid abuse and dependence among physicians: hypotheses and treatment. Harvard Review of Psychiatry 2008, 16(3):181-194.
130. Merlo L.J., Gold M.S. Special report - frontiers in psychiatric research: addiction research: the state of the art in 2008. Psychiatric Times 2008, 25(7):52-57.
131. DuPont R.L., McLellan A.T., White W.L., Merlo L.J., Gold M.S. Setting the standard for recovery: physicians' health programs. J Subst Abuse Treat 2009, 36(2):159-171.
132. Giordano J., Blum k Probing the mysteries of recovery through nutrigenomic and holistic medicine: "Science Meets Recovery" through Seminal Translational Research. Prof Councelor Mag 2010, 11(5):10-16.
133. McLellan A.T., Skipper G.S., Campbell M., DuPont R.L. Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. BMJ (Clinical research edition) 2008, 337:1-6.
134. Conner B.T., Hellemann G.S., Ritchie T.L., Noble E.P. Genetic, personality, and environmental predictors of drug use in adolescents. J Subst Abuse Treat 2010, 38(2):178-190.
135. Mizrahi R., Houle S., Vitcu I., Ng A., Wilson A.A. Side effects profile in humans of (11)C-(+)-PHNO, a dopamine D(2/3) agonist ligand for PET. J Nucl Med 2010, 51(3):496-497.